Financial
1. Reported quarter: Lilly finished 2025 on a much higher revenue and earnings platform
Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%); FY2025 revenue $65.2B (+45%)
The company exited 2025 at a materially higher scale than it entered the year. Revenue rose from $12.7 billion in Q1 to $19.3 billion in Q4, while EPS expanded sharply as volume growth from cardiometabolic medicines flowed through a high-margin pharma model.
Revenue climbed quarter after quarter through 2025
Q1 to Q4 2025 revenue: $12.73B, $15.56B, $17.60B, $19.29B
Revenue moved higher every quarter in 2025, which matters because it shows Lilly's growth was not a one-quarter spike. The company kept add…
Non-GAAP EPS also stepped up materially
Q1 to Q4 2025 non-GAAP EPS: $3.34, $6.31, $7.02, $7.54
Non-GAAP EPS rose sharply through the year as scale, product mix and manufacturing efficiency improved. This is the cleaner read on underly…
Reported EPS still carried acquisition and R&D noise
Q4 reported EPS $7.39 included $0.52 of acquired IPR&D charges; FY2025 reported EPS $22.95 vs. non-GAAP EPS $24.21
Lilly's reported EPS remained strong, but it still reflected acquisition and IPR&D-related charges. For valuation work, investors should an…
Operations
2. Tirzepatide is the dominant commercial flywheel: Mounjaro and Zepbound now define the company
Q4 Mounjaro $7.41B; Q4 Zepbound $4.26B; FY2025 Mounjaro $23.0B; FY2025 Zepbound $13.5B; together about 56% of total FY2025 revenue
Lilly's current earnings power is being driven primarily by tirzepatide across diabetes and obesity. Mounjaro and Zepbound are no longer simply high-growth products; together they are now the center of the firm's revenue model, manufacturing priorities and market narrative.
Mounjaro kept compounding at extraordinary scale
Q1 to Q4 2025 Mounjaro revenue: $3.84B, $5.20B, $6.52B, $7.41B
Mounjaro's quarterly revenue growth shows that demand for diabetes and cardiometabolic use cases remained intense even as the product scale…
Zepbound became a second megablockbuster almost immediately
Q1 to Q4 2025 Zepbound revenue: $2.31B, $3.38B, $3.59B, $4.26B
Zepbound scaled from $2.3 billion in Q1 to $4.3 billion in Q4, showing that Lilly successfully converted obesity demand into a major second…
Tirzepatide concentration is now both a strength and a risk
Mounjaro + Zepbound FY2025 revenue about $36.5B vs. total revenue $65.2B
Having two products generate more than half of total revenue is extraordinarily powerful in the near term, but it also means Lilly is incre…
Operations
3. Manufacturing expansion and product mix helped translate demand into margin strength
Q4 gross margin 82.5%; Q2 non-GAAP gross margin 85.0%; 2025 manufacturing expansion continued across the U.S. and Europe
The commercial story works only if Lilly can manufacture enough product and improve cost absorption as volumes rise. During 2025, management consistently linked stronger margins to improved cost of production and favorable mix, while also continuing to add new capacity to support future demand.
Gross margin stayed structurally strong through the year
Q1 to Q4 2025 gross margin %: 82.5%, 84.3%, 82.9%, 82.5%
Gross margin remained above 82% all year, which is a sign that Lilly is monetizing its scale efficiently even while demand, product launche…
Manufacturing expansion is strategic, not optional
2025 included announcements for new and expanded facilities in Virginia, Texas, Puerto Rico, Pennsylvania, Alabama and Europe
Lilly repeatedly highlighted manufacturing expansion during 2025 because supply is one of the main constraints on how much demand it can co…
Lower realized prices are still the main drag within a strong margin story
Q1 to Q4 2025 price impact: -6%, -6%, -10%, -5%
In every quarter of 2025, Lilly reported meaningful negative price effects even while volumes surged. That means the company is currently w…
Product
4. Lilly is still investing aggressively so the story extends beyond one obesity cycle
Q4 R&D $3.8B; 2025 R&D remained near 20% of revenue; orforglipron, retatrutide, oncology and immunology assets advanced materially
Lilly is not behaving like a company trying to harvest one blockbuster wave. It is reinvesting heavily into next-generation obesity, diabetes, oncology and immunology programs so that the current tirzepatide cash flow can fund the next product cycle.
R&D spending stayed high as the pipeline advanced
Q1 to Q4 2025 R&D: $2.73B, $3.34B, $3.47B, $3.8B
R&D spending climbed through the year, which shows Lilly is deliberately reinvesting into the pipeline rather than maximizing current opera…
Orforglipron became the clearest next commercial layer
By Q4 2025 Lilly had submitted orforglipron for obesity in the U.S. and Japan and for obesity and type 2 diabetes in the EU
Orforglipron matters because it gives Lilly a potential oral obesity and diabetes growth vector that can broaden the incretin franchise bey…
The late-stage pipeline keeps widening the optionality set
Positive orforglipron, retatrutide, Jaypirca, Taltz/Zepbound and other trial or regulatory updates during 2025
Lilly's 2025 pipeline updates matter because they show management is building multiple follow-on value pools rather than relying on a singl…
Risk
5. The main risk is not weak demand; it is whether concentration, reimbursement and supply complexity become the bottleneck
2025 growth was volume-led, while the 10-K explicitly flags dependence on relatively few products or product classes and on a consolidated supply chain
Lilly's near-term risk profile is unusual because demand is not the problem. The more important risks are concentrated product exposure, pricing and access pressure, manufacturing execution, and the challenge of meeting extremely high expectations while expanding globally.
The company itself identifies concentration and supply-chain dependence as key risks
10-K risk factor: dependence on relatively few products or product classes for a significant percentage of total revenue and a consolidated supply chain
This disclosure matters because it confirms that management understands the current model is highly concentrated. If supply, regulatory, pr…
Access expansion is strategically positive but can reinforce price pressure
Lilly announced an agreement with the U.S. government to expand access to obesity medicines to millions of Americans
The access agreement is potentially demand-accretive and strategically important, but it also underscores that the obesity opportunity will…
Market
6. 2026 guidance says the story is still scaling, but the market will now judge margin durability as much as revenue growth
2026 guidance: revenue $80B-$83B; non-GAAP EPS $33.50-$35.00; performance margin 46.0%-47.5%
Management's 2026 guide implies another major step-up in scale from FY2025 revenue of $65.2 billion. At this size, however, investors are no longer only asking whether Lilly can grow quickly. They are asking whether the company can preserve gross margin quality, fund the pipeline, and expand capacity without losing too much to pricing and mix pressure.
The guide implies another year of very large absolute growth
2026 midpoint revenue guidance $81.5B vs. FY2025 revenue $65.2B
An $81.5 billion midpoint implies that Lilly is still expecting massive absolute revenue expansion even after a 45% growth year in 2025. Th…
From here, the quality of growth matters more than the existence of growth
watch supply conversion, price realization, pipeline diversification and cost discipline
The next stage of the Lilly story will be judged less on whether tirzepatide keeps growing and more on whether that growth remains high qua…